Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.43 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ILK | Q13418 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27998626 | 0.85 | ASH1L (0.43) | ALDH1A1ASH1LMAPTMEN1KMT2A | |
| SCHEMBL984327 | 0.81 | ILK (0.59) | ALDH1A1ASH1LMAPTMEN1KMT2A | |
| SCHEMBL17859467 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTHPGDILKNR4A1 | |
| SCHEMBL5118299 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL8975728 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CASP7MAPTMEN1KMT2A | |
| SCHEMBL20969720 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL260372 | 0.77 | ALDH1A1 (0.51) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL5116616 | 0.77 | SMN1; SMN2 (0.51) | ALDH1A1HPGDDHODHNPC1RAB9A | |
| SCHEMBL7556888 | 0.77 | ALDH1A1 (0.45) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| Bromide SCHEMBL261347 | 0.76 | ALDH1A1 (0.50) | ALDH1A1MAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107419310-B | Trivalent chromium plating layer and preparation method thereof | 永星化工(上海)有限公司 | 2020-01-03 | — | — | CN | claimed |
| CN-107419310-A | A kind of trivalent chrome plating and preparation method thereof | 永星化工(上海)有限公司 | 2017-12-01 | — | — | CN | claimed |
| CN-117126578-B | Organosilicon polymer/POSS hybrid antifouling coating grafted with antibacterial molecules and preparation method thereof | 中国科学院海洋研究所 | 2025-04-22 | — | — | CN | disclosed |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2024-08-01 | — | — | US | disclosed |
| CN-117126578-A | Organosilicon polymer/POSS hybrid antifouling coating grafted with antibacterial molecules and preparation method thereof | 中国科学院海洋研究所 | 2023-11-28 | — | — | CN | disclosed |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20220220097-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-07-14 | — | — | US | disclosed |
| EP-3521286-B1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-11124501-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-09-21 | — | — | US | disclosed |
| CN-107419310-B | Trivalent chromium plating layer and preparation method thereof | 永星化工(上海)有限公司 | 2020-01-03 | — | — | CN | disclosed |
| EP-3521286-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | Cancer Research Technology Ltd. (GB) | 2019-08-07 | — | — | EP | disclosed |
| CN-100484937-C | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARM CORP (US) | 2009-05-06 | — | — | CN | disclosed |
| CN-101001856-A | Indazoles, benzothiazoles, benzisothiazoles, benzisoxazoles, and preparation and use thereof | MEMORY PHARM CORP (US) | 2007-07-18 | — | — | CN | disclosed |
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | QLT INC. (CA) | 2006-11-02 | — | — | US | disclosed |
| CN-1684962-A | Indazoles, benzothiazoles, and benzisothiazoles, and preparation and use thereof | MEMORY PHARM CORP (US) | 2005-10-19 | — | — | CN | disclosed |
| EP-1542997-A2 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | QLT, Inc. (CA) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004011460-A2 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | QLT, INC. (CA) | 2004-02-05 | — | — | WO | disclosed |
| EP-0003035-B1 | PROCESS FOR THE PREPARATION OF POLYMERS OF VINYL CHLORIDE AND REACTOR FOR CARRYING OUT THE PROCESS | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-03-24 | — | — | EP | disclosed |
| US-4256854-A | ANTIDEPOSIT AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-03-17 | — | — | US | disclosed |
| EP-0003035-A2 | Process for the preparation of polymers of vinyl chloride and reactor for carrying out the process | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | TST, PTK2, PTK2B | ALDH1A1 2466/4885ASH1L 3237/4885G6PD 1532/4885 |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | ALDH1A1 408/4885ASH1L 2907/4885G6PD 835/4885 |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | HSF1, HSP90AB1, HSPB1 | ALDH1A1 408/4885ASH1L 2907/4885G6PD 835/4885 |
| US-20220220097-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | ALDH1A1 408/4885ASH1L 2907/4885G6PD 835/4885 |
| US-11124501-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | HSF1, HSP90AB1, HSPB1 | ALDH1A1 541/4885ASH1L 3442/4885G6PD 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.